Description:
The LumiraDx SARS-CoV-2 Ag Test is a rapid microfluidic immunofluorescence assay for use with the LumiraDx Platform intended for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2 directly from nasal swab specimens collected from individuals suspected of, or at increased risk of, COVID-19 by their healthcare provider within the first twelve days of symptom onset.
Save this product for later
Sign up to receive public health supply chain news from PFSCM
